title: Favorable Impact on LDL Particle Size in Response to Treatment With Pioglitazone is Associated With Less Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes.
authors.forename: Preethi
authors.initials: P
authors.lastname: Mani
authors.forename: Kiyoko
authors.initials: K
authors.lastname: Uno
authors.forename: Julie
authors.initials: J
authors.lastname: St John
authors.forename: Stuart
authors.initials: S
authors.lastname: Kupfer
authors.forename: Alfonso
authors.initials: A
authors.lastname: Perez
authors.forename: E Murat
authors.initials: EM
authors.lastname: Tuzcu
authors.forename: Stanley L
authors.initials: SL
authors.lastname: Hazen
authors.forename: Steven E
authors.initials: SE
authors.lastname: Nissen
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Nicholls
mesh_terms: D001682:Biological Availability; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D018450:Disease Progression; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000097:blood / Q000737:chemistry; D010316:Particle Size; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
chemical_list: D007004:Hypoglycemic Agents; D008077:Lipoproteins, LDL; D045162:Thiazolidinediones; D000077205:Pioglitazone